What is the comparison between Dicyclomine (Anticholinergic) and Hyoscyamine (Anticholinergic) for the treatment of Irritable Bowel Syndrome (IBS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Dicyclomine is the preferred anticholinergic medication for treating irritable bowel syndrome (IBS) due to its selective action on the digestive tract and potentially fewer systemic side effects, as suggested by the latest guidelines 1. When considering the treatment of IBS with anticholinergic medications, it's essential to weigh the benefits and side effects of each option.

  • Dicyclomine (typically 10-20mg taken 4 times daily) is often preferred for its selective action on the digestive tract, which may result in fewer systemic side effects compared to other anticholinergics like hyoscyamine.
  • Hyoscyamine (0.125-0.25mg taken 3-4 times daily or 0.375-0.75mg extended-release twice daily) works more quickly but may cause more widespread anticholinergic effects, making it less ideal for long-term management but potentially useful for acute symptom flares. Both medications aim to relax smooth muscle in the digestive tract, reducing painful spasms and cramping associated with IBS.
  • The choice between dicyclomine and hyoscyamine should consider the need for immediate relief versus the preference for a medication with fewer side effects for ongoing management, with dicyclomine being favored for the latter due to its pharmacological profile and the findings from recent guidelines 1. It's crucial to note that neither dicyclomine nor hyoscyamine should be used in patients with certain conditions such as glaucoma, urinary retention, severe ulcerative colitis, or myasthenia gravis, highlighting the importance of careful patient selection and monitoring 1.

From the Research

Comparison of Dicyclomine and Hyoscyamine for IBS

  • Dicyclomine and hyoscyamine are two antispasmodics used to treat irritable bowel syndrome (IBS) symptoms, particularly abdominal pain and cramps 2.
  • According to a study published in 1999, dicyclomine is useful for patients with daily symptoms, especially after meals, while hyoscyamine is often used for patients with infrequent but severe episodes of unpredictable pain 2.
  • A 2006 study found that dicyclomine and hyoscyamine, the two myorelaxants available in the United States, have not been proven effective in reducing abdominal pain in patients with IBS 3.
  • However, a 2011 systematic review found that antispasmodics, including dicyclomine, are effective for the treatment of IBS, with a significant benefit for improvement of abdominal pain, global assessment, and symptom score 4.
  • Another study published in 2011 provided a comprehensive evidence-based review of the efficacy of medications to treat IBS symptoms and found that dicyclomine and hyoscyamine are effective for treating IBS symptoms, including abdominal pain and bloating 5.
  • A 2014 review of medication management of IBS found that dicyclomine and peppermint oil have reliable evidence supporting their use for the treatment of IBS symptoms 6.

Efficacy of Dicyclomine and Hyoscyamine

  • The efficacy of dicyclomine and hyoscyamine may depend on the individual patient and the specific symptoms being treated 4, 5.
  • Dicyclomine may be more effective for patients with daily symptoms, while hyoscyamine may be more effective for patients with infrequent but severe episodes of unpredictable pain 2.
  • Both dicyclomine and hyoscyamine may be used intermittently in response to periods of increased abdominal pain, cramps, and urgency 2.

Side Effects and Interactions

  • The side effects and interactions of dicyclomine and hyoscyamine were not extensively discussed in the provided studies, but it is essential to consider these factors when prescribing these medications for IBS treatment 2, 3, 4, 6, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Irritable Bowel Syndrome.

Current treatment options in gastroenterology, 1999

Research

Current gut-directed therapies for irritable bowel syndrome.

Current treatment options in gastroenterology, 2006

Research

Treatment of irritable bowel syndrome.

Journal of clinical pharmacy and therapeutics, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.